About
Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- San Diego, US
Contact Information
Find more investors like Sorrento
Search Investors